Amgen (AMGN) Shareholder Capital Management Has Trimmed Its Position as Valuation Declined; Dreman Value Management Lowered Holding in Amgen Common Stock Usd.000 (AMGN) by $983,411

June 21, 2018 - By Maria Brooks

Amgen Inc. (NASDAQ:AMGN) Logo

David Dreman decreased its stake in Amgen Inc Common Stock Usd.000 (AMGN) by 96.2% based on its latest 2018Q1 regulatory filing with the SEC. Dreman Value Management Llc sold 5,819 shares as the company’s stock declined 5.44% with the market. The hedge fund run by David Dreman held 230 shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $39,000, down from 6,049 at the end of the previous reported quarter. Dreman Value Management Llc who had been investing in Amgen Inc Common Stock Usd.000 for a number of months, seems to be less bullish one the $122.53B market cap company. The stock decreased 0.72% or $1.34 during the last trading session, reaching $185.17. About 260,155 shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 14.68% since June 21, 2017 and is uptrending. It has outperformed by 2.11% the S&P500. Some Historical AMGN News: 19/03/2018 – Mersana Strengthens Bd of Directors Leadership With Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen; 24/04/2018 – Amgen posts higher 1st-quarter profit as sales rise 3 percent; 24/04/2018 – AMGEN CHIEF FINL OFFICER DAVID MELINE SPEAKS ON CONF. CALL; 21/05/2018 – FDA OKS PROLIA® (DENOSUMAB) FOR GLUCOCORTICOID-INDUCED; 16/05/2018 – Amgen Receives European Commission Approval for Repatha(R) (Evolocumab) to Prevent Heart Attack and Stroke in Adults With Established Cardiovascular Disease; 07/03/2018 – AMGEN INC AMGN.O SETS QUARTERLY DIVIDEND OF $1.32/SHR; 18/05/2018 – Novartis, Amgen: Aimovig Is Migraine Prevention Drug; 16/05/2018 – AMGEN: EC APPROVES REPATHA TO PREVENT HEART ATTACK, STROKE; 19/05/2018 – Egan Bernal Becomes First Colombian Amgen Tour of California Champion; Countryman Fernando Gaviria Sweeps Sprint Stages at; 11/04/2018 – Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira® (adalimumab)

Capital Management Corp decreased its stake in Amgen Inc (AMGN) by 33.65% based on its latest 2018Q1 regulatory filing with the SEC. Capital Management Corp sold 17,622 shares as the company’s stock declined 5.44% with the market. The institutional investor held 34,750 shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $5.92 million, down from 52,372 at the end of the previous reported quarter. Capital Management Corp who had been investing in Amgen Inc for a number of months, seems to be less bullish one the $122.53B market cap company. The stock decreased 0.72% or $1.34 during the last trading session, reaching $185.17. About 260,155 shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 14.68% since June 21, 2017 and is uptrending. It has outperformed by 2.11% the S&P500. Some Historical AMGN News: 24/04/2018 – Amgen Sees FY Rev $21.9B-$22.8B; 19/05/2018 – Egan Bernal Becomes First Colombian Amgen Tour of California Champion; Countryman Fernando Gaviria Sweeps Sprint Stages at Sacramento Race Conclusion; 05/04/2018 – AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes With Samsung Bioepis; 25/05/2018 – FDA CONFIRMS ORPHAN DRUG STATUS FOR AMGEN’S ROMIPLOSTIM; 08/03/2018 – Amgen Announces Final Results Of Tender Offer; 16/03/2018 – FDA: Biologic License Application (BLA): 761024 Company: AMGEN INC; 26/04/2018 – Humira Helps AbbVie — Earnings Review; 26/04/2018 – AbbVie’s beat fueled by demand for Humira, Hep C drugs; 12/03/2018 – Regeneron CEO Leonard Schleifer says the biotech firm will lower the price of Praluent so long as insurers increase access to patients; 10/04/2018 – Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant

Among 25 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Therefore 44% are positive. Amgen Inc. had 89 analyst reports since August 3, 2015 according to SRatingsIntel. Argus Research maintained the stock with “Buy” rating in Thursday, July 27 report. As per Thursday, January 18, the company rating was maintained by Piper Jaffray. On Tuesday, June 13 the stock rating was maintained by Oppenheimer with “Buy”. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Buy” rating by Deutsche Bank on Friday, July 31. Piper Jaffray maintained the stock with “Buy” rating in Thursday, October 12 report. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Hold” rating by BMO Capital Markets on Friday, October 20. The firm has “Buy” rating by Cowen & Co given on Thursday, February 1. On Friday, February 2 the stock rating was maintained by Credit Suisse with “Neutral”. The firm has “Market Perform” rating by BMO Capital Markets given on Friday, February 2. On Monday, February 5 the stock rating was downgraded by Atlantic Securities to “Hold”.

Since January 16, 2018, it had 0 insider purchases, and 6 insider sales for $1.65 million activity.

Investors sentiment decreased to 0.88 in Q1 2018. Its down 0.34, from 1.22 in 2017Q4. It dived, as 67 investors sold AMGN shares while 557 reduced holdings. 114 funds opened positions while 435 raised stakes. 502.72 million shares or 8.88% less from 551.71 million shares in 2017Q4 were reported. Gideon Incorporated stated it has 0.22% of its portfolio in Amgen Inc. (NASDAQ:AMGN). 9,935 are held by Founders Capital Mngmt Limited Company. Alpha Cubed Ltd Liability Corp invested in 100,558 shares or 2.24% of the stock. Brave Asset Management Inc owns 9,569 shares. Clearbridge Invests Ltd Limited Liability Company holds 0.95% or 5.91 million shares in its portfolio. Founders Fin Securities Limited Company holds 0.32% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 5,865 shares. Primecap Mngmt Communication Ca, a California-based fund reported 21.44M shares. Rodgers Brothers owns 5,374 shares or 0.3% of their US portfolio. Fishman Jay A Mi accumulated 64,035 shares. Clean Yield Gp has 1.51% invested in Amgen Inc. (NASDAQ:AMGN) for 20,916 shares. Alpine Woods Cap Investors Ltd reported 0.2% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Holderness Co holds 0.51% or 6,041 shares. Baxter Bros accumulated 3,547 shares. Arvest Fincl Bank Trust Division stated it has 1,720 shares. Hartline Investment Corp owns 10,742 shares or 0.52% of their US portfolio.

More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: Seekingalpha.com which released: “Amgen Should Rebound On Aimovig And Kyprolis Revenue” on June 20, 2018, also Seekingalpha.com with their article: “Amgen Has Me Worried Therefore Selling Calls” published on May 31, 2018, Seekingalpha.com published: “EC grants full approval for Amgen’s Blincyto” on June 19, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Fool.com and their article: “Is Amgen Inc. (AMGN) a Buy?” published on June 03, 2018 as well as Streetinsider.com‘s news article titled: “Amgen (AMGN) Granted EC Full Marketing Approval to Add Overall Survival Data To BLINCYTO (blinatumomab) Label” with publication date: June 19, 2018.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on July, 24. They expect $3.52 EPS, up 7.65% or $0.25 from last year’s $3.27 per share. AMGN’s profit will be $2.33B for 13.15 P/E if the $3.52 EPS becomes a reality. After $3.47 actual EPS reported by Amgen Inc. for the previous quarter, Wall Street now forecasts 1.44% EPS growth.

Capital Management Corp, which manages about $401.58 million and $371.47M US Long portfolio, upped its stake in Gentex Corp (NASDAQ:GNTX) by 152,370 shares to 658,113 shares, valued at $15.15 million in 2018Q1, according to the filing. It also increased its holding in Applied Matls Inc (NASDAQ:AMAT) by 36,245 shares in the quarter, for a total of 171,117 shares, and has risen its stake in Alphabet Inc.

More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: Fool.com which released: “Is Amgen Inc. (AMGN) a Buy?” on June 03, 2018, also Seekingalpha.com with their article: “Amgen Has Me Worried Therefore Selling Calls” published on May 31, 2018, Seekingalpha.com published: “EC grants full approval for Amgen’s Blincyto” on June 19, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Streetinsider.com and their article: “Amgen (AMGN) Granted EC Full Marketing Approval to Add Overall Survival Data To BLINCYTO (blinatumomab) Label” published on June 19, 2018 as well as Seekingalpha.com‘s news article titled: “Amgen Should Rebound On Aimovig And Kyprolis Revenue” with publication date: June 20, 2018.

Among 25 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Therefore 44% are positive. Amgen Inc. had 89 analyst reports since August 3, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, September 7 by UBS. The stock has “Buy” rating by Oppenheimer on Monday, June 26. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Buy” rating by Deutsche Bank on Friday, July 31. The stock of Amgen Inc. (NASDAQ:AMGN) has “Neutral” rating given on Wednesday, September 28 by Citigroup. The company was maintained on Friday, September 22 by BMO Capital Markets. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Outperform” rating by RBC Capital Markets on Friday, July 31. The stock has “Buy” rating by Mizuho on Tuesday, November 8. Cowen & Co maintained it with “Buy” rating and $20900 target in Thursday, July 20 report. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Buy” rating by Oppenheimer on Tuesday, June 13. The firm has “Hold” rating given on Friday, August 26 by Gabelli.

Investors sentiment decreased to 0.88 in Q1 2018. Its down 0.34, from 1.22 in 2017Q4. It dropped, as 67 investors sold AMGN shares while 557 reduced holdings. 114 funds opened positions while 435 raised stakes. 502.72 million shares or 8.88% less from 551.71 million shares in 2017Q4 were reported. The Michigan-based Sigma Planning has invested 0.2% in Amgen Inc. (NASDAQ:AMGN). Zevenbergen Invests Ltd Liability Co accumulated 2,565 shares. Fund Evaluation Grp Ltd Liability reported 9,415 shares stake. Smead Capital Mgmt stated it has 6.13% in Amgen Inc. (NASDAQ:AMGN). D L Carlson Invest Gp Inc Inc holds 0.07% or 1,270 shares. Reliance Tru Of Delaware, Delaware-based fund reported 9,084 shares. West Chester Inc accumulated 7,932 shares. Sabal Tru invested in 145,718 shares. Bp Pcl accumulated 115,000 shares or 0.71% of the stock. Martin And Tn holds 0.68% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 12,062 shares. Frontier Invest Company reported 7,367 shares. Moreover, Farmers Commercial Bank has 0.7% invested in Amgen Inc. (NASDAQ:AMGN) for 6,641 shares. Pittenger Anderson reported 27,435 shares or 0.41% of all its holdings. Somerset Trust Communications has 1.63% invested in Amgen Inc. (NASDAQ:AMGN). Alpha Windward Limited Liability Corp has 0.2% invested in Amgen Inc. (NASDAQ:AMGN).

Amgen Inc. (NASDAQ:AMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Maria Brooks

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: